|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-4-2
|
|
pubmed:abstractText |
The Breast Cancer Prevention Trial demonstrated that tamoxifen treatment produced a 49% reduction in the risk of invasive breast cancer among women at elevated risk for the disease. The U.S. Food and Drug Administration (FDA) subsequently approved tamoxifen for women aged 35 years or older with a 5-year breast cancer risk of 1.67% or higher for breast cancer chemoprevention. However, tamoxifen use has been associated with adverse outcomes, and not all eligible women have a positive benefit/risk ratio.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
2
|
|
pubmed:volume |
95
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
526-32
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12671020-Adult,
pubmed-meshheading:12671020-African Americans,
pubmed-meshheading:12671020-Age Factors,
pubmed-meshheading:12671020-Aged,
pubmed-meshheading:12671020-Anticarcinogenic Agents,
pubmed-meshheading:12671020-Antineoplastic Agents, Hormonal,
pubmed-meshheading:12671020-Breast Neoplasms,
pubmed-meshheading:12671020-Confidence Intervals,
pubmed-meshheading:12671020-Cross-Sectional Studies,
pubmed-meshheading:12671020-Drug Prescriptions,
pubmed-meshheading:12671020-Eligibility Determination,
pubmed-meshheading:12671020-European Continental Ancestry Group,
pubmed-meshheading:12671020-Female,
pubmed-meshheading:12671020-Hispanic Americans,
pubmed-meshheading:12671020-Humans,
pubmed-meshheading:12671020-Middle Aged,
pubmed-meshheading:12671020-Questionnaires,
pubmed-meshheading:12671020-Risk Assessment,
pubmed-meshheading:12671020-Risk Factors,
pubmed-meshheading:12671020-Selective Estrogen Receptor Modulators,
pubmed-meshheading:12671020-Tamoxifen,
pubmed-meshheading:12671020-United States,
pubmed-meshheading:12671020-United States Food and Drug Administration
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention.
|
|
pubmed:affiliation |
Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-7344, USA. Andrew_Freedman@nih.gov
|
|
pubmed:publicationType |
Journal Article
|
